General Catalyst Group Management’s Parabilis Medicines Inc PBLS Stock Holding History

General Catalyst Group Management’s Portfolio PBLS Stock Details PBLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$43.8M	Buy	+1,600,937	New	+$44.2M	23.24%	2

Other funds holding PBLS

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

General Catalyst Group Management's PBLS Position: Q2 2026 in Review

General Catalyst Group Management opened a new position in Parabilis Medicines Inc (PBLS) in Q2 2026: 1,600,937 shares worth $43.8M. The stake represents 23.24% of the portfolio and ranks #2 among its holdings.

79 funds tracked by Wall St. Rank hold PBLS as of Q2 2026.

General Catalyst Group Management held 1,600,937 shares of Parabilis Medicines Inc worth $43.8M as of Q2 2026.
Parabilis Medicines Inc was a new General Catalyst Group Management position in Q2 2026.
Parabilis Medicines Inc made up 23.24% of General Catalyst Group Management's portfolio in Q2 2026, its #2 holding.
79 funds tracked by Wall St. Rank held Parabilis Medicines Inc as of Q2 2026.

Based on General Catalyst Group Management's 13F filing for Q2 2026, filed 17 Aug 2026.